\square

Stock Option (right to

buy)

Remarks:

\$<mark>0.96</mark>

Explanation of Responses:

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							11 30(11) 0	n uic	investment	001	прапу Ас	01134	10							
1. Name and Address of Reporting Person [*] Steele Robin Joan					2. Issuer Name and Ticker or Trading Symbol Dare Bioscience, Inc. [DARE]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Steere</u>	KUUIII JU	<u>a11</u>													X Directo	or		10% Ov	ner	
(Last)	(F		3. Date of Earliest Transaction (Month/Day/Year) 06/21/2023									Officer below)	(give title		Other (s below)	pecify				
3655 NOBEL DRIVE					A If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6.1	6. Individual or Joint/Group Filing (Check Applicable					
SUITE 2	260				4. 11/	Amen	iument, L	Jale	or Original r	neu		ay/rea	ai)	Line	e)				•	
,															X Form f	iled by One	e Repo	orting Perso	n	
(Street)		•	00400												Form f Persor		re thar	n One Repo	rting	
SAN DI	EGO C	A	92122			1. 4		1 (.)	· -		• • • • •	P	•							
Rule 10b5-1(c) Transaction Indication																				
(City)	(5	State)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Tab	le I - Nor	n-Deriv	ative	Sec	urities	a Ac	quired, I	Dis	posed c	of, or	Ben	eficial	ly Owned	d				
1. Title of Security (Instr. 3) 2. Transa Date (Month/Data)				Execution Date,		Code (Instr. 5)						Benefici	es For ially (D) Following (I) (n: Direct r Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount		(A) or (D)	Price	Transac (Instr. 3	tion(s)			(insti. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Conversion Date Execurity or Exercise (Month/Day/Year) if a			3A. Deeme Execution if any (Month/Day	n Date, Transaction Code (Instr.		tion 1str.	of		6. Date Exercisable and Expiration Date (Month/Day/Year)			Secur Under Deriva	unt of rities erlying	ecurity 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(: (Instr. 4)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Г										Amount					1	

Date Exercisable

(1)

(D)

1. This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer.

40,000

Expiration Date

06/21/2033

Title

Common stock

<u>/s/Lisa Walters-Hoffert,</u> <u>Attorney-in-fact</u>

<u>06/21/2023</u>

\$<mark>0</mark>

40,000

D

** Signature of Reporting Person Date

or Number

Shares

40,000

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/21/2023

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

A

V (A)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.